I must admit this is the most fascinating board. So many bona fide experts all in one place. Amarantus is not a one trick pony; MANF is their flagship product and really what this company's future is all about.
Also, Eltoprazine has enormous potential and will be in a Phase 2b trial soon. Yes, it would be ideal to fund MANF trials internally; so I hope LymPro turns out to be a huge success (only time will tell; but anybody who has drawn any conclusion that it has failed is full of crap).
The LymPro data was only an interim look based a very small patient population. Do we know whether LymPro will succeed or fail? Absolutely not...the capability to tweak the sensitivity still exists to a much higher rate exists. See excerpt from today press release stated below:
"Our ability to fine tune the assay to optimize for sensitivity in an Alzheimer's cohort, while retaining acceptable specificity in the non-Alzheimer's cohort is extremely valuable. We are looking forward to completing enrollment in this trial and analyzing the full dataset?.
As always, please do your own due diligence as trusting anybody here is hazardous to your wealth building potential. Trust in you Mgt. team (and be patient; the one's who cry wolf are the ones who wanted to make an overnight fortune ...Wall Street is much smarter than most of you...but many dont see how the forces control the trading price to wear down the retail crowd).
Lastly, if you adjust your time horizon as to how you define success; you will then realize that the day to day trading price is irrelevant...the PPS is going significantly higher folks.
